Krop I E, Sgroi D, Porter D A, Lunetta K L, LeVangie R, Seth P, Kaelin C M, Rhei E, Bosenberg M, Schnitt S, Marks J R, Pagon Z, Belina D, Razumovic J, Polyak K
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801. doi: 10.1073/pnas.171138398. Epub 2001 Jul 31.
To identify molecular alterations implicated in the initiating steps of breast tumorogenesis, we compared the gene expression profiles of normal and ductal carcinoma in situ (DCIS) mammary epithelial cells by using serial analysis of gene expression (SAGE). Through the pair-wise comparison of normal and DCIS SAGE libraries, we identified several differentially expressed genes. Here, we report the characterization of one of these genes, HIN-1 (high in normal-1). HIN-1 expression is significantly down regulated in 94% of human breast carcinomas and in 95% of preinvasive lesions, such as ductal and lobular carcinoma in situ. This decrease in HIN-1 expression is accompanied by hypermethylation of its promoter in the majority of breast cancer cell lines (>90%) and primary tumors (74%). HIN-1 is a putative cytokine with no significant homology to known proteins. Reintroduction of HIN-1 into breast cancer cells inhibits cell growth. These results indicate that HIN-1 is a candidate tumor suppressor gene that is inactivated at high frequency in the earliest stages of breast tumorogenesis.
Proc Natl Acad Sci U S A. 2001-8-14
Clin Cancer Res. 1997-10
Cancer Res. 2001-8-1
BMC Med Genomics. 2025-7-21
Nat Rev Urol. 2022-11
Pharmacol Ther. 2022-8
Prostate. 2019-8-21
J Histochem Cytochem. 2019-2-15
Braz J Otorhinolaryngol. 2017-8-1
J Mammary Gland Biol Neoplasia. 2000-4
Science. 2000-8-18
Am J Pathol. 2000-6
Annu Rev Physiol. 2000
Proc Natl Acad Sci U S A. 2000-5-23
J Natl Cancer Inst. 2000-4-5
Trends Genet. 2000-4
Mech Dev. 2000-3-15